To further investigate whether PTBP1 and PKM2 have synergistic or additive effects in MM patients' outcome, 351 myeloma patients were divided into 3 subgroups including PTBP1 low/PKM2 low, PTBP1 mid/PKM2 mid, and PTBP1 high/PKM2 high, and survival curve showed that the PTBP1 high/PKM2 high group has the worst outcome in OS (p < 0.0001, Figure 5(c)). The gene discussed is PTBP1; the disease is plasma cell myeloma.